Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands

Voxzogo reimbursement Netherlands hangs in limbo after Biomarin’s decision on March 12, 2026, to withdraw its application, leaving children with achondroplasia without access despite parental pleas. Zorginstituut Nederland voices deep regret over the move, citing petitions like one with 34,615 signatures by September 23, 2025, and urges the manufacturer to reverse course.

Parental Pleas Ignored by Biomarin

Biomarin has refused to pursue Voxzogo reimbursement Netherlands, despite urgent requests from parents of children with achondroplasia, a form of dwarfism. Zorginstituut organized special meetings with parents, patients, healthcare professionals, and Biomarin to discuss conditional reimbursement, highlighting the agency’s commitment amid the manufacturer’s inaction.

Zorginstituut Nederland proactively consulted Biomarin multiple times after Voxzogo’s 2021 EMA approval, an rare initiative since no reimbursement application followed. These steps aimed to aid a small patient group, while emphasizing the manufacturer’s responsibility.

Fallout for Patients and Market Access

Biomarin’s stance denies Dutch children a globally available therapy, fueling frustration and Zorginstituut’s reversal call. It highlights orphan drug pricing tensions, potentially deterring submissions in cost-conscious markets like the Netherlands. This stresses discussions for sustainable Voxzogo reimbursement in the Netherlands.